[Omalizumab (Xolair). Product description].
Xolair, Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding site on human immunoglobulin E (IgE). Currently, omalizumab has been approved for the treatment of persistent allergic asthma in patients who are poorly controlled with inhaled corticosteroids. However, other allergic disorders may be amenable to treatment with omalizumab because of its ability to inhibit effector functions of IgE. Treatment with omalizumab should be administered by specialists with training in diagnosis and treatment of allergic asthma. The treatment should be withheld if no positive treatment effects are observed after 4 months.
Laursen
Lars Christian
LC
Herlev Hospital, Medicinsk Afdeling J 106. lclaursen@dadlnet.dk
D000328:Adult; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D006801:Humans; D007279:Injections, Subcutaneous; D000069444:Omalizumab; D017455:Receptors, IgE / Q000378:metabolism; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017455:Receptors, IgE; D000069444:Omalizumab